The first FDA-approved prescription medication for the treatment of primary hyperoxaluria type 1 (PH1).
OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine in children and adults.
OXLUMO works by reducing oxalate production in infants, children, and adults
OXLUMO is a prescription medication for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in infants, children, and adults.
What to expect from treatment with OXLUMO
Learn about how OXLUMO is given.
CONNECT WITH AN EDUCATOR
Learn about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO® from one of our trained Alnylam Patient Education Liaisons (PELs).
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
We’re with you throughout your treatment journey
Find support that can help you and your family during treatment with OXLUMO.
Sign up for updates
Learn more by signing up to receive important content.